Table 2.

Correlation analysis between Lg FGF19 and other parameters.

	Control		T2DM		HCC		T2DM-HCC
	r	p	r	p	r	p	r	p
Age	−0.215	0.282	0.176	0.381	0.168	0.533	0.056	0.877
BMI	−0.242	0.224	0.006	0.975	0.481	0.059	−0.390	0.265
FPG	−0.273	0.168	0.047	0.815	0.162	0.550	0.395	0.259
ALT†	−0.152	0.451	−0.409	0.034	−0.068	0.802	0.145	0.690
γGT†	−0.450	0.018	−0.042	0.836	0.536	0.032	0.357	0.311
ALB	−0.266	0.179	−0.371	0.057	−0.036	0.894	−0.104	0.774
TBA†	0.400	0.039	0.477	0.012	0.684	0.003	0.673	0.033
TBIL†	−0.363	0.063	−0.035	0.861	−0.103	0.704	0.010	0.978
eGFR†	0.424	0.027	−0.005	0.980	0.062	0.819	0.047	0.898
Cys-C∗	−0.227	0.255	0.384	0.048	−0.058	0.833	−0.300	0.400
TC	−0.485	0.010	−0.070	0.728	0.026	0.923	−0.333	0.347
TG	−0.333	0.090	−0.229	0.251	−0.220	0.413	−0.064	0.861
LDL	−0.528	0.005	0.132	0.511	0.024	0.931	−0.079	0.828
AFP†	0.001	0.998	0.140	0.486	0.540	0.031	0.560	0.092
CEA†	−0.081	0.689	−0.091	0.650	0.078	0.774	0.464	0.177

^†Log-transformed variables; Pearson correlation analysis for normally distributed variables; ^∗Spearman correlation analysis for nonnormally distributed variables; control: healthy control; T2DM: newly diagnosed type 2 diabetes mellitus patients; HCC: newly diagnosed hepatocellular carcinoma patients; T2DM-HCC: type 2 diabetes mellitus combined newly diagnosed hepatocellular carcinoma patients. Total: total population. Abbreviations are same as in Table 1. p values <0.05 were considered significant.